Bio-AMD, Inc.; Ethics Approval for Patient Testing Study
London, England July 2, 2015; Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together “Bio-AMD”, “We” or the “Company” OTCQB: BIAD) is pleased to announce it has obtained a “favourable ethical opinion” from the North West Centre of Research Ethics Committees of the UK’s National Research Ethics Service (together, “NRES”), enabling it to undertake sample testing from patients as part of its development program.
NRES provides a robust framework aimed at protecting the rights, safety, dignity and well-being of research participants and is responsible for the facilitation and promotion of ethical research.
NRES ethical approval is a prerequisite for the development of a medical device requiring human sample testing. Consent is only given in circumstances where there is a potential benefit to participants, science and society. The Company is pleased to have secured this robustly examined approval and believes that it further validates the potential for its technology platforms. The testing will be conducted in conjunction with the Wythenshawe Hospital, part of the University Hospital of South Manchester NHS Foundation Trust.
Dr Djennati, Managing Director of Bio Alternative Medical Devices Ltd., said: “We are delighted to have received approval for testing and to be working with the Wythenshawe UHSM, which has an excellent research reputation.”
About Bio-AMD, Inc.
Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and WOCU Ltd, the owner of the WOCU®, a global currency data reference source for application in financial markets. (www.wocu.com).
To find out more about Bio-AMD (OTCQB: BIAD), visit our website at www.bioamd.com.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” “believes” and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 30, 2015, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Bio-AMD, Inc.
Tom Barr, CEO
+44 (0)8445 861 910